Development of a Soluplus budesonide freeze-dried powder for nasal drug delivery

References

• Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm. 2009;379:146–157.
   PubMed Web of Science ®Google Scholar
• Costantino HR, Illum L, Brandt G, et al. Intranasal delivery: Physicochemical and therapeutic aspects. Int J Pharm. 2007;337:1–24.
   PubMed Web of Science ®Google Scholar
• Illum L. Nasal drug delivery - recent developments and future prospects. J Control Release. 2012;161:254–263.
   PubMed Web of Science ®Google Scholar
• Illum L. Nasal drug delivery-possibilities, problems and solutions. J Control Release. 2003;87:187–198.
   PubMed Web of Science ®Google Scholar
• Behl CR, Pimplaskar HK, Sileno AP, et al. Effects of physicochemical properties and other factors on systemic nasal drug delivery. Adv Drug Deliv Rev. 1998;29:89–116.
   PubMed Web of Science ®Google Scholar
• Li BV, Jin F, Lee SL, et al. Bioequivalence for locally acting nasal spray and nasal aerosol products: standard development and generic approval. AAPS J. 2013;15:875–883.
   PubMed Web of Science ®Google Scholar
• Kim J-E, Cho H-J, Kim D-D. Budesonide/cyclodextrin complex-loaded lyophilized microparticles for intranasal application. Drug Dev Ind Pharm. 2014;40:743–748.
   PubMed Web of Science ®Google Scholar
• Cho H-J, Balakrishnan P, Shim W-S, et al. Characterization and in vitro evaluation of freeze-dried microparticles composed of granisetron-cyclodextrin complex and carboxymethylcellulose for intranasal delivery. Int J Pharm. 2010;400:59–65.
   PubMed Web of Science ®Google Scholar
• Devalia JL, Prime D, Richards DH. Effect of Variable Inspiratory Flow Rate on the Performance of the Budesonide Rhinocort Turbuhaler™. Clin Drug Investig. 2001;21:195–201.
   PubMed Web of Science ®Google Scholar
• Punčochová K, Vukosavljevic B, Hanuš J, et al. Non-invasive insight into the release mechanisms of a poorly soluble drug from amorphous solid dispersions by confocal Raman microscopy. Eur J Pharm Biopharm. 2016;101:119–125.
   PubMed Web of Science ®Google Scholar
• Lu J, Cuellar K, Hammer NI, et al. Solid-state characterization of Felodipine-Soluplus amorphous solid dispersions. Drug Dev Ind Pharm. 2016;42:485–496.
   PubMed Web of Science ®Google Scholar
• Savjani KT, Gajjar AK, Savjani JK. Drug solubility: importance and enhancement techniques. ISRN Pharm. 2012;2012:195727–195710.
   PubMedGoogle Scholar
• Lewis AL, Jordan F, Illum L. CriticalSorb™: enabling systemic delivery of macromolecules via the nasal route. Drug Deliv Transl Res. 2012;3:26–32.
   Web of Science ®Google Scholar
• Shamma R, Elkasabgy N. Design of freeze-dried Soluplus/polyvinyl alcohol-based film for the oral delivery of an insoluble drug for the pediatric use. Drug Deliv. 2016;23:489–499.
   PubMed Web of Science ®Google Scholar
• Lavra ZM, Pereira de Santana MD, Ré MI. Solubility and dissolution performances of spray-dried solid dispersion of Efavirenz in Soluplus. Drug Dev Ind Pharm. 2017;43:42–54.
   PubMed Web of Science ®Google Scholar
• Shamma RN, Basha M. Soluplus®: A novel polymeric solubilizer for optimization of Carvedilol solid dispersions: Formulation design and effect of method of preparation. Powder Technol. 2013;237:406–414.
   Web of Science ®Google Scholar
• Lust A, Strachan CJ, Veski P, et al. Amorphous solid dispersions of piroxicam and Soluplus(®): Qualitative and quantitative analysis of piroxicam recrystallization during storage. Int J Pharm. 2015;486:306–314.
   PubMed Web of Science ®Google Scholar
• Tanaka A, Furubayashi T, Matsushita A, et al. Nasal absorption of macromolecules from powder formulations and effects of sodium carboxymethyl cellulose on their absorption. PLoS One. 2016;11:e0159150.
   PubMed Web of Science ®Google Scholar
• OkudaOkamoto M, Nomura MY, Saito Y. Clinical study on beclomethasone dipropionate powder preparation (TL-102) in perennial nasal allergy. Rhinology. 1986;24:113–123.
   PubMedGoogle Scholar
• Balducci AG, Ferraro L, Bortolotti F, et al. Antidiuretic effect of desmopressin chimera agglomerates by nasal administration in rats. Int J Pharm. 2013;440:154–160.
   PubMed Web of Science ®Google Scholar
• Colombo G, Lorenzini L, Zironi E, et al. Brain distribution of ribavirin after intranasal administration. Antiviral Res. 2011;92:408–414.
   PubMed Web of Science ®Google Scholar
• PozzoliTraini M, Fabio DS, Young PM, Ong HX. Transport of beclometasone dipropionate across RPMI 2650 model of nasal epithelium: evaluation of two different approaches to drug delivery. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM, Traini D, editors. Respiratory drug delivery 2016. Richmond (VA): Virginia Commonwealth University; 2106. Vol. 3: p. 607–610.
   Google Scholar
• Ishikawa F, Murano M, Hiraishi M, et al. Insoluble powder formulation as an effective nasal drug delivery system. Pharm Res. 2002;19:1097–1104.
   PubMed Web of Science ®Google Scholar
• Balducci AG, Magosso E, Colombo G, et al. Agglomerated oral dosage forms of artemisinin/β-cyclodextrin spray-dried primary microparticles showing increased dissolution rate and bioavailability. AAPS PharmSciTech. 2013;14:911–918.
   PubMed Web of Science ®Google Scholar
• Djupesland PG, Skretting A. Nasal deposition and clearance in man: comparison of a bidirectional powder device and a traditional liquid spray pump. J Aerosol Med Pulmon Drug Deliv. 2012;25:280–289.
   PubMed Web of Science ®Google Scholar
• Ishikawa F, Katsura M, Tamai I, et al. Improved nasal bioavailability of elcatonin by insoluble powder formulation. Int J Pharm. 2001;224:105–114.
   PubMed Web of Science ®Google Scholar
• RussoButtini P, Sonvico FF, Bettini R. Chimeral agglomerates of microparticles for the administration of caffeine nasal powders. J Drug Del Sci Tech. 2004;14:449–454.
   Web of Science ®Google Scholar
• Naikwade SR, Bajaj AN. Development of validated specific HPLC method for budesonide and characterization of its alkali degradation product. Can J Anal Sci Spect. 2008;53:113–122.
   Google Scholar
• Pozzoli M, Ong HX, Morgan L, et al. Application of RPMI 2650 nasal cell model to a 3D printed apparatus for the testing of drug deposition and permeation of nasal products. Eur J Pharm Biopharm. 2016;107:223–233.
   PubMed Web of Science ®Google Scholar
• Pozzoli M, Rogueda P, Zhu B, et al. Dry powder nasal drug delivery: challenges, opportunities and a study of the commercial Teijin Puvlizer Rhinocort device and formulation. Drug Dev Ind Pharm. 2016;42:1660–1668.
   PubMed Web of Science ®Google Scholar
• Dayal P, Shaik MS, Singh M. Evaluation of different parameters that affect droplet-size distribution from nasal sprays using the Malvern Spraytec. J Pharm Sci. 2004;93:1725–1742.
   PubMed Web of Science ®Google Scholar
• Doub WH, Adams WP, Wokovich AM, et al. Measurement of drug in small particles from aqueous nasal sprays by Andersen Cascade Impactor. Pharm Res. 2012;29:3122–3130.
   PubMed Web of Science ®Google Scholar
• FDA CDER, Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action. 2003.
   Google Scholar
• British Pharmacopoeia Commission. Appendix XII C. Consistency of formulated preparations. In: British Pharmacopoeia. London: TSO; 2016. Volume IV.
   Google Scholar
• Reichl S, Becker K. Cultivation of RPMI 2650 cells as an in-vitro model for human transmucosal nasal drug absorption studies: optimization of selected culture conditions. J Pharm Pharmacol. 2012;64:1621–1630.
   PubMed Web of Science ®Google Scholar
• Bai S, Yang T, Abbruscato TJ, et al. Evaluation of human nasal RPMI 2650 cells grown at an air-liquid interface as a model for nasal drug transport studies. J Pharm Sci. 2008;97:1165–1178.
   PubMed Web of Science ®Google Scholar
• Kreft ME, Jerman UD, Lasič E, et al. The characterization of the human nasal epithelial cell line RPMI 2650 under different culture conditions and their optimization for an appropriate in vitro nasal model. Pharm Res. 2015;32:665–679.
   PubMed Web of Science ®Google Scholar
• Flanner JW, Moore HH. Mathematical comparison of dissolution profiles. Pharm Technol 1996;20:64–74.
   Google Scholar
• Salama RO, Traini D, Chan H-K, et al. Preparation and characterisation of controlled release co-spray dried drug-polymer microparticles for inhalation 2: evaluation of in vitro release profiling methodologies for controlled release respiratory aerosols. Eur J Pharm Biopharm. 2008;70:145–152.
   PubMed Web of Science ®Google Scholar
• Mezzena M, Scalia S, Young PM, et al. Solid lipid budesonide microparticles for controlled release inhalation therapy. AAPS J. 2009;11:771–778.
   PubMed Web of Science ®Google Scholar
• Cirri M, Roghi A, Valleri M, et al. Development and characterization of fast-dissolving tablet formulations of glyburide based on solid self-microemulsifying systems. Eur J Pharm Biopharm. 2016;104:19–29.
   PubMed Web of Science ®Google Scholar
• Khadka P, Ro J, Kim H, et al. Pharmaceutical particle technologies: an approach to improve drug solubility, dissolution and bioavailability. Asian J Pharm Sci. 2014;9:304–316.
   Google Scholar
• Müller T, Scherließ R, Schiewe J, et al. Applicability of the one-step DVS method for the determination of amorphous amounts for further different hydrophilic and hydrophobic drugs. Eur J Pharm Biopharm. 2015;94:333–341.
   PubMed Web of Science ®Google Scholar
• Nagy ZK, Balogh A, Vajna B, et al. Comparison of electrospun and extruded Soluplus®-based solid dosage forms of improved dissolution. J Pharm Sci. 2012;101:322–332.
   PubMed Web of Science ®Google Scholar
• Linn M, Collnot E-M, Djuric D, et al. Soluplus® as an effective absorption enhancer of poorly soluble drugs in vitro and in vivo. Eur J Pharm Sci. 2012;45:336–343.
   PubMed Web of Science ®Google Scholar
• Yu L. Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv Drug Deliv Rev. 2001;48:27–42.
   PubMed Web of Science ®Google Scholar
• Liu J, Zou M, Piao H, et al. Characterization and pharmacokinetic study of Aprepitant solid dispersions with Soluplus®. Molecules. 2015;20:11345–11356.
   PubMed Web of Science ®Google Scholar
• Cheng YS, Holmes TD, Gao J, et al. Characterization of nasal spray pumps and deposition pattern in a replica of the human nasal airway. J Aerosol Med. 2001;14:267–280.
   PubMedGoogle Scholar
• Dolberg AM, Reichl S. Expression of P-glycoprotein in excised human nasal mucosa and optimized models of RPMI 2650 cells. Int J Pharm. 2016;508:22–33.
   PubMed Web of Science ®Google Scholar